CMS aiming for more transparency in drug pricing negotiations
by
Contributor since / Followers
Contributor since / Followers
2 months ago
Olivier Le Moal The U.S. Centers for Medicare & Medicaid Services, or CMS, said it
ABBV
Allergan Aesthetics launches new AA signature program at IMCAS 2025
by
Contributor since / Followers
Contributor since / Followers
2 months ago
Klaus Vedfelt/DigitalVision via Getty Images Allergan Aesthetics, an AbbVie (NYSE:ABBV) company, Tuesday unveiled the new
AbbVie closes $200M Nimble Therapeutics acquisition
by
Contributor since / Followers
Contributor since / Followers
2 months ago
SB AbbVie (NYSE:ABBV) has completed its $200M acquisition of Nimble Therapeutics. Nimble’s lead asset is
AbbVie, Neomorph to develop molecular glue degraders
by
Contributor since / Followers
Contributor since / Followers
2 months ago
hapabapa AbbVie (NYSE:ABBV) has entered into a collaboration agreement with Neomorph for the development of
Chinese biotech dominance in R&D is on the rise
by
Contributor since / Followers
Contributor since / Followers
2 months ago
narvikk/E+ via Getty Images Against a backdrop of rising U.S.-China geopolitical tensions, there are signs
Pharma lobby slams IRA, PBMs as Medicare lists 15 more drugs for price setting
by
Contributor since / Followers
Contributor since / Followers
2 months ago
wildpixel/iStock via Getty Images As Medicare announced a fresh set of drugs selected for its
Wegovy included as Medicare lists 15 drugs selected for next pricing negotiations
by
Contributor since / Followers
Contributor since / Followers
2 months ago
wingedwolf The Centers for Medicare and Medicaid Services (CMS) on Friday announced 15 additional Medicare
AbbVie retains Humira market share above 70%: report
by
Contributor since / Followers
Contributor since / Followers
2 months ago
vzphotos/iStock Editorial via Getty Images AbbVie (NYSE:ABBV) has managed to keep its market share for
AbbVie may commit less capital to psych drugs: report
by
Contributor since / Followers
Contributor since / Followers
2 months ago
hapabapa AbbVie (NYSE:ABBV) reportedly may commit less capital to the development of psychiatric drugs in
AbbVie goes ex dividend tomorrow
by
Contributor since / Followers
Contributor since / Followers
3 months ago
AbbVie (NYSE:ABBV) had declared $1.64/share quarterly dividend. Payable Feb. 14; for shareholders of record Jan.